These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 23782935)

  • 41. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.
    Carobbio A; Finazzi G; Antonioli E; Guglielmelli P; Vannucchi AM; Dellacasa CM; Salmoiraghi S; Delaini F; Rambaldi A; Barbui T
    Exp Hematol; 2009 Sep; 37(9):1016-21. PubMed ID: 19559071
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression analysis of microRNA-125 in patients with polycythemia vera and essential thrombocythemia and correlation with JAK2 allele burden and laboratory findings.
    Ferdowsi S; Atarodi K; Amirizadeh N; Toogeh G; Azarkeivan A; Shirkoohi R; Faranoush M; Vaezi M; Alimoghaddam K; Ghavamzadeh A; Naghadeh HT; Ghaffari SH
    Int J Lab Hematol; 2015 Oct; 37(5):661-7. PubMed ID: 26011312
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
    Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
    Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms.
    Alvarez-Larrán A; Angona A; Martínez-Avilés L; Bellosillo B; Besses C
    Leuk Res; 2012 Mar; 36(3):324-6. PubMed ID: 22001278
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera.
    Riley CH; Brimnes MK; Hansen M; Jensen MK; Hasselbalch HC; Kjaer L; Straten PT; Svane IM
    Eur J Haematol; 2016 Jul; 97(1):83-92. PubMed ID: 26385526
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.
    Lussana F; Carobbio A; Salmoiraghi S; Guglielmelli P; Vannucchi AM; Bottazzi B; Leone R; Mantovani A; Barbui T; Rambaldi A
    J Hematol Oncol; 2017 Feb; 10(1):54. PubMed ID: 28228104
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.
    Tashi T; Swierczek S; Kim SJ; Salama ME; Song J; Heikal N; King KY; Hickman K; Litton S; Prchal JT
    Leukemia; 2018 Aug; 32(8):1830-1833. PubMed ID: 29556018
    [No Abstract]   [Full Text] [Related]  

  • 48. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.
    Verger E; Soret-Dulphy J; Maslah N; Roy L; Rey J; Ghrieb Z; Kralovics R; Gisslinger H; Grohmann-Izay B; Klade C; Chomienne C; Giraudier S; Cassinat B; Kiladjian JJ
    Blood Cancer J; 2018 Oct; 8(10):94. PubMed ID: 30287855
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
    Vainchenker W; Kralovics R
    Blood; 2017 Feb; 129(6):667-679. PubMed ID: 28028029
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.
    Kuriakose E; Vandris K; Wang YL; Chow W; Jones AV; Christos P; Cross NC; Silver RT
    Haematologica; 2012 Apr; 97(4):538-42. PubMed ID: 22102708
    [TBL] [Abstract][Full Text] [Related]  

  • 52. No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation.
    Gau JP; Chen CC; Chou YS; Liu CJ; Yu YB; Hsiao LT; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH
    Blood Cells Mol Dis; 2015 Jun; 55(1):36-9. PubMed ID: 25976465
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis.
    Bewersdorf JP; Giri S; Wang R; Podoltsev N; Williams RT; Tallman MS; Rampal RK; Zeidan AM; Stahl M
    Leukemia; 2021 Jun; 35(6):1643-1660. PubMed ID: 32868875
    [TBL] [Abstract][Full Text] [Related]  

  • 54. JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.
    Godfrey AL; Chen E; Pagano F; Ortmann CA; Silber Y; Bellosillo B; Guglielmelli P; Harrison CN; Reilly JT; Stegelmann F; Bijou F; Lippert E; McMullin MF; Boiron JM; Döhner K; Vannucchi AM; Besses C; Campbell PJ; Green AR
    Blood; 2012 Sep; 120(13):2704-7. PubMed ID: 22898600
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A TET2 rs3733609 C/T genotype is associated with predisposition to the myeloproliferative neoplasms harboring JAK2(V617F) and confers a proliferative potential on erythroid lineages.
    Shen XH; Sun NN; Yin YF; Liu SF; Liu XL; Peng HL; Dai CW; Xu YX; Deng MY; Luo YY; Zheng WL; Zhang GS
    Oncotarget; 2016 Feb; 7(8):9550-60. PubMed ID: 26843622
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
    Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA
    BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
    Ganly P; Hanrahan V; Baker B; Romeril K
    Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
    [TBL] [Abstract][Full Text] [Related]  

  • 58. JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events.
    Alvarez-Larrán A; Bellosillo B; Pereira A; Kerguelen A; Hernández-Boluda JC; Martínez-Avilés L; Fernández-Rodríguez C; Gómez M; Lombardía L; Angona A; Ancochea A; Senín A; Longarón R; Navarro B; Collado M; Besses C
    Am J Hematol; 2014 May; 89(5):517-23. PubMed ID: 24458835
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
    Mascarenhas J; Kosiorek HE; Prchal JT; Rambaldi A; Berenzon D; Yacoub A; Harrison CN; McMullin MF; Vannucchi AM; Ewing J; O'Connell CL; Kiladjian JJ; Mead AJ; Winton EF; Leibowitz DS; De Stefano V; Arcasoy MO; Kessler CM; Catchatourian R; Rondelli D; Silver RT; Bacigalupo A; Nagler A; Kremyanskaya M; Levine MF; Arango Ossa JE; McGovern E; Sandy L; Salama ME; Najfeld V; Tripodi J; Farnoud N; Penson AV; Weinberg RS; Price L; Goldberg JD; Barbui T; Marchioli R; Tognoni G; Rampal RK; Mesa RA; Dueck AC; Hoffman R
    Blood; 2022 May; 139(19):2931-2941. PubMed ID: 35007321
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.
    Finazzi G; Barbui T
    Leukemia; 2008 Aug; 22(8):1494-502. PubMed ID: 18596737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.